StimCell Enegetics

StimCell Enegetics EBIT per Share

The EBIT per Share of StimCell Enegetics (STME) as of Oct 21, 2026 is -0.04 USD. In the previous year, EBIT per Share was -0.02 USD — a change of 59.04% (lower).

EBIT per Share

-0.04USD

YoY

59.04%

Last updated:

EBIT per Share of StimCell Enegetics is 2026 -0.04 USD. EBIT per Share of StimCell Enegetics was 2025 -0.02 USD. It decreases by 59.04% lower compared to the previous year.

The StimCell Enegetics EBIT per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Share
Date
EBIT per Share
Jan 1, 2021
-0.01 USD
Jan 1, 2022
-0.01 USD
Jan 1, 2023
-0.01 USD
Jan 1, 2024
-0.02 USD
Jan 1, 2025
-0.02 USD
Jan 1, 2026
-0.04 USD
Jan 1, 2027 (e)
0.00 USD
Jan 1, 2028 (e)
0.00 USD
The StimCell Enegetics EBIT per Share history
YEAREBIT per ShareYoY
est0.00USD—
est0.00USD-100.00%
-0.04USD+59.04%
-0.02USD+54.29%
-0.02USD+122.32%
-0.01USD-33.35%
-0.01USD0.00%
-0.01USD-38.95%
-0.02USD-7.26%
-0.02USD-45.63%
-0.03USD-6.42%
-0.04USD+9.20%
-0.03USD-50.01%
-0.07USD+11,257.76%
-0.00USD+46.62%
-0.00USD-20.32%
-0.00USD+13.19%
-0.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

StimCell Enegetics Stock analysis

What does StimCell Enegetics do? Cell MedX Corp. makes money through its subsidiary Avyonce Cosmedics Inc., which resells spa technology and equipment to the beauty and wellness industry. Avyonce also markets eBalance Technology, used for micro current treatments targeting diabetes and related ailments, and conducts observational studies with this technology. The company provides continuing education for estheticians and healthcare professionals in medical aesthetics. Avyonce Cosmedics Inc. serves the beauty and wellness industry, focusing on professionals who use spa technology and equipment. The firm develops a family of devices based on eBalance Technology, which is applied in treatments for diabetes and related conditions. This technology is central to Avyonce's product offerings and educational services. Cell MedX Corp. operates as a development stage company with no full-time employees, relying on its subsidiary Avyonce to drive revenue. The company's business model centers on the commercialization of eBalance Technology through product sales, educational programs, and observational studies in the medical aesthetics sector. StimCell Enegetics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about StimCell Enegetics stock

EBIT per Share of StimCell Enegetics is -0.04 USD in 2026.

EBIT per Share of StimCell Enegetics changed from -0.02 USD to -0.04 USD, representing a 59.04% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Share StimCell Enegetics since 2006 – with annual values, charts, and detailed analysis.

EBIT per Share measures operating profit allocated to each outstanding share.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — StimCell Enegetics

All Key Metrics — StimCell Enegetics